AbbVie to Announce Q2 2026 Financial Results on July 31
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 45 minutes ago
0mins
Source: PRnewswire
- Earnings Announcement Schedule: AbbVie is set to release its Q2 2026 financial results before the market opens on July 31, reflecting the company's commitment to financial transparency and potentially boosting investor confidence.
- Live Webcast Conference: The company will host a live webcast of the earnings conference call at 8 a.m. Central Time, accessible via AbbVie's Investor Relations website, enhancing interaction and communication with investors.
- Performance Review: This earnings report will cover AbbVie's latest advancements in key therapeutic areas such as immunology, neuroscience, and oncology, showcasing the company's efforts and achievements in addressing serious health issues.
- Mission Statement: AbbVie is dedicated to discovering and delivering innovative medicines and solutions aimed at improving people's quality of life, emphasizing its significant role in the healthcare industry and future growth potential.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ABBV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ABBV
Wall Street analysts forecast ABBV stock price to rise
18 Analyst Rating
12 Buy
6 Hold
0 Sell
Moderate Buy
Current: 243.140
Low
223.00
Averages
252.00
High
289.00
Current: 243.140
Low
223.00
Averages
252.00
High
289.00
About ABBV
AbbVie Inc. is a global, diversified, research-based biopharmaceutical company. It is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. The aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Duodopa is a levodopa-carbidopa intestinal gel for the treatment of Parkinson's disease. Eye care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
AbbVie to Announce Q2 2026 Financial Results on July 31
- Earnings Announcement: AbbVie will release its Q2 2026 financial results on July 31 before market open, providing crucial financial metrics and business performance updates that will assist investors in assessing the company's financial health.
- Live Webcast: The company will host a live webcast of the earnings conference call at 8 a.m. Central time, accessible through AbbVie's Investor Relations website, ensuring transparency and enhancing engagement with investors.
- Performance Review and Outlook: This earnings report will cover AbbVie's latest advancements in key therapeutic areas such as immunology, neuroscience, and oncology, reflecting the company's efforts and achievements in addressing significant health issues, which may impact future market performance.
- Company Mission and Vision: AbbVie is committed to discovering and delivering innovative medicines that address current and future medical challenges, emphasizing its products and services within the Allergan Aesthetics portfolio, showcasing the company's long-term strategic positioning in the healthcare industry.
See More
AbbVie Announces $10.9 Billion Acquisition of Apogee Therapeutics
- Acquisition Overview: AbbVie announced its acquisition of Apogee Therapeutics for $10.9 billion, paying $135.11 per share in cash, which represents a 49% premium over Apogee's closing price last week, thereby enhancing AbbVie's competitive edge in immunology.
- Pipeline Advantage: Apogee's lead drug, zumilokibart, targets IL-13 and is expected to compete with Dupixent; if successful, it could reshape patient preferences and unlock over $10 billion in market potential.
- Financial Strength: AbbVie plans to fund the acquisition entirely with strong operating cash flows, avoiding dilution of existing shareholders, and reported $15 billion in revenue in Q1, a 12% year-over-year increase, indicating robust financial health.
- Risk and Reward: While the acquisition carries clinical and regulatory risks, AbbVie does not expect it to be accretive to adjusted EPS until 2032; however, its extensive market experience and strong sales team may mitigate these risks.
See More
AbbVie to Announce Q2 2026 Financial Results on July 31
- Earnings Announcement Schedule: AbbVie is set to release its Q2 2026 financial results before the market opens on July 31, reflecting the company's commitment to financial transparency and potentially boosting investor confidence.
- Live Webcast Conference: The company will host a live webcast of the earnings conference call at 8 a.m. Central Time, accessible via AbbVie's Investor Relations website, enhancing interaction and communication with investors.
- Performance Review: This earnings report will cover AbbVie's latest advancements in key therapeutic areas such as immunology, neuroscience, and oncology, showcasing the company's efforts and achievements in addressing serious health issues.
- Mission Statement: AbbVie is dedicated to discovering and delivering innovative medicines and solutions aimed at improving people's quality of life, emphasizing its significant role in the healthcare industry and future growth potential.
See More
Comparative Growth Strategies of AbbVie and Pfizer
- AbbVie's Growth Potential: AbbVie reported approximately $61.2 billion in revenue for FY 2025, reflecting an 8.7% increase, with a net income of about $4.3 billion, indicating that its strategy focusing on high-margin specialty medicines is effective despite biosimilar competition pressures.
- Pfizer's Diversification Strategy: Pfizer generated nearly $62.6 billion in revenue for FY 2025, a slight decline of 1.6%, but net income reached $7.8 billion, showcasing its efforts to diversify through acquisitions and expand its vaccine product lines to mitigate patent expirations, particularly in oncology.
- Patent Risks and Market Competition: AbbVie faces significant patent risks with core products like Humira, compounded by pricing pressures from the Inflation Reduction Act, potentially leading to revenue declines, while Pfizer is navigating a patent cliff and intense competition from rivals in the vaccine market.
- Future Outlook and Investor Confidence: AbbVie is expected to see net income soar to $14.6 billion in FY 2026, while Pfizer's net income is projected to increase by 40% to over $11 billion, although both companies will rely on FDA decisions and new product launches to sustain long-term growth.
See More
Dividend Investment Comparison: AbbVie vs. Pfizer
- Financial Performance Comparison: AbbVie reported nearly $61.2 billion in revenue for FY 2025, an 8.7% increase, with a net income of approximately $4.3 billion, showcasing strong growth potential in high-margin specialty medicines; in contrast, Pfizer's revenue was about $62.6 billion, a slight decline of 1.6%, yet it achieved a net income close to $7.8 billion, reflecting ongoing efforts in vaccine and drug development.
- Market Risk Analysis: AbbVie faces significant risks from patent expirations and biosimilar competition, particularly threatening Humira's market position, while needing to successfully integrate the acquisition of Apogee Therapeutics to meet growth targets; Pfizer is also approaching a patent cliff with several blockbuster drugs losing exclusivity, compounded by high debt levels and competitive pressures.
- Future Growth Expectations: AbbVie's net income is projected to soar to $14.6 billion by 2026, with sales growing to $67.2 billion, driven by successful launches of new products like Skyrizi and Rinvoq; Pfizer's net income is expected to jump by 40% to over $11 billion, with sales slightly increasing to $61.7 billion, although future sales may decline due to expiring patents.
- Investment Valuation Assessment: AbbVie has a forward P/E ratio of 16.6x and a P/S ratio of 6.8x, indicating investor confidence in its future earnings; Pfizer's lower forward P/E of 8.2x and P/S ratio of 2.2x suggest a lower current valuation, reflecting market uncertainty about its growth prospects.
See More
Conexeu Sciences Targets GLP-1 Aesthetics Market with Innovative Platform
- Market Validation: Galderma's presentation of clinical data on its injectables (Sculptra, Restylane) addressing medication-induced facial volume loss signifies that the 'Ozempic face' category has gained formal recognition, catalyzing rapid growth in the aesthetics industry.
- Surge in Patient Demand: In 2024, U.S. plastic surgeons treated over 837,000 GLP-1 patients, indicating a swift rise in demand for facial restoration, which highlights the substantial potential and business opportunities within this emerging market.
- Technological Innovation: Conexeu's CXU™ platform features a thermosensitive collagen scaffold designed for tissue regeneration rather than mere filling, with a targeted FDA 510(k) submission planned for early 2027, which could open new market avenues for the company if successful.
- Competitive Landscape: As a newly public entity, Conexeu faces competition from established players like Galderma, yet its unique regenerative technology may allow it to carve out a niche in the rapidly expanding aesthetics market.
See More
AbbVie to Announce Q2 2026 Financial Results on July 31
- Earnings Announcement: AbbVie will release its Q2 2026 financial results on July 31 before market open, providing crucial financial metrics and business performance updates that will assist investors in assessing the company's financial health.
- Live Webcast: The company will host a live webcast of the earnings conference call at 8 a.m. Central time, accessible through AbbVie's Investor Relations website, ensuring transparency and enhancing engagement with investors.
- Performance Review and Outlook: This earnings report will cover AbbVie's latest advancements in key therapeutic areas such as immunology, neuroscience, and oncology, reflecting the company's efforts and achievements in addressing significant health issues, which may impact future market performance.
- Company Mission and Vision: AbbVie is committed to discovering and delivering innovative medicines that address current and future medical challenges, emphasizing its products and services within the Allergan Aesthetics portfolio, showcasing the company's long-term strategic positioning in the healthcare industry.
See More
AbbVie Announces $10.9 Billion Acquisition of Apogee Therapeutics
- Acquisition Overview: AbbVie announced its acquisition of Apogee Therapeutics for $10.9 billion, paying $135.11 per share in cash, which represents a 49% premium over Apogee's closing price last week, thereby enhancing AbbVie's competitive edge in immunology.
- Pipeline Advantage: Apogee's lead drug, zumilokibart, targets IL-13 and is expected to compete with Dupixent; if successful, it could reshape patient preferences and unlock over $10 billion in market potential.
- Financial Strength: AbbVie plans to fund the acquisition entirely with strong operating cash flows, avoiding dilution of existing shareholders, and reported $15 billion in revenue in Q1, a 12% year-over-year increase, indicating robust financial health.
- Risk and Reward: While the acquisition carries clinical and regulatory risks, AbbVie does not expect it to be accretive to adjusted EPS until 2032; however, its extensive market experience and strong sales team may mitigate these risks.
See More
AbbVie to Announce Q2 2026 Financial Results on July 31
- Earnings Announcement Schedule: AbbVie is set to release its Q2 2026 financial results before the market opens on July 31, reflecting the company's commitment to financial transparency and potentially boosting investor confidence.
- Live Webcast Conference: The company will host a live webcast of the earnings conference call at 8 a.m. Central Time, accessible via AbbVie's Investor Relations website, enhancing interaction and communication with investors.
- Performance Review: This earnings report will cover AbbVie's latest advancements in key therapeutic areas such as immunology, neuroscience, and oncology, showcasing the company's efforts and achievements in addressing serious health issues.
- Mission Statement: AbbVie is dedicated to discovering and delivering innovative medicines and solutions aimed at improving people's quality of life, emphasizing its significant role in the healthcare industry and future growth potential.
See More
Comparative Growth Strategies of AbbVie and Pfizer
- AbbVie's Growth Potential: AbbVie reported approximately $61.2 billion in revenue for FY 2025, reflecting an 8.7% increase, with a net income of about $4.3 billion, indicating that its strategy focusing on high-margin specialty medicines is effective despite biosimilar competition pressures.
- Pfizer's Diversification Strategy: Pfizer generated nearly $62.6 billion in revenue for FY 2025, a slight decline of 1.6%, but net income reached $7.8 billion, showcasing its efforts to diversify through acquisitions and expand its vaccine product lines to mitigate patent expirations, particularly in oncology.
- Patent Risks and Market Competition: AbbVie faces significant patent risks with core products like Humira, compounded by pricing pressures from the Inflation Reduction Act, potentially leading to revenue declines, while Pfizer is navigating a patent cliff and intense competition from rivals in the vaccine market.
- Future Outlook and Investor Confidence: AbbVie is expected to see net income soar to $14.6 billion in FY 2026, while Pfizer's net income is projected to increase by 40% to over $11 billion, although both companies will rely on FDA decisions and new product launches to sustain long-term growth.
See More
Dividend Investment Comparison: AbbVie vs. Pfizer
- Financial Performance Comparison: AbbVie reported nearly $61.2 billion in revenue for FY 2025, an 8.7% increase, with a net income of approximately $4.3 billion, showcasing strong growth potential in high-margin specialty medicines; in contrast, Pfizer's revenue was about $62.6 billion, a slight decline of 1.6%, yet it achieved a net income close to $7.8 billion, reflecting ongoing efforts in vaccine and drug development.
- Market Risk Analysis: AbbVie faces significant risks from patent expirations and biosimilar competition, particularly threatening Humira's market position, while needing to successfully integrate the acquisition of Apogee Therapeutics to meet growth targets; Pfizer is also approaching a patent cliff with several blockbuster drugs losing exclusivity, compounded by high debt levels and competitive pressures.
- Future Growth Expectations: AbbVie's net income is projected to soar to $14.6 billion by 2026, with sales growing to $67.2 billion, driven by successful launches of new products like Skyrizi and Rinvoq; Pfizer's net income is expected to jump by 40% to over $11 billion, with sales slightly increasing to $61.7 billion, although future sales may decline due to expiring patents.
- Investment Valuation Assessment: AbbVie has a forward P/E ratio of 16.6x and a P/S ratio of 6.8x, indicating investor confidence in its future earnings; Pfizer's lower forward P/E of 8.2x and P/S ratio of 2.2x suggest a lower current valuation, reflecting market uncertainty about its growth prospects.
See More
Conexeu Sciences Targets GLP-1 Aesthetics Market with Innovative Platform
- Market Validation: Galderma's presentation of clinical data on its injectables (Sculptra, Restylane) addressing medication-induced facial volume loss signifies that the 'Ozempic face' category has gained formal recognition, catalyzing rapid growth in the aesthetics industry.
- Surge in Patient Demand: In 2024, U.S. plastic surgeons treated over 837,000 GLP-1 patients, indicating a swift rise in demand for facial restoration, which highlights the substantial potential and business opportunities within this emerging market.
- Technological Innovation: Conexeu's CXU™ platform features a thermosensitive collagen scaffold designed for tissue regeneration rather than mere filling, with a targeted FDA 510(k) submission planned for early 2027, which could open new market avenues for the company if successful.
- Competitive Landscape: As a newly public entity, Conexeu faces competition from established players like Galderma, yet its unique regenerative technology may allow it to carve out a niche in the rapidly expanding aesthetics market.
See More
